Table 3.

Descriptive characteristics, including drug resistance prior to starting therapy and at the time of failure, of the children in each group with confirmed viral failure

Group	Sex	Age treatme nt started	Age at rando m	Viral load at random	Age at first >1000cp m	Viral load at failure	Pre- treatment drug resistance*	NNRTI resistance at failure	NRTI resistance at failure
LPV/r control	F	11	25	<400	37	6920	-	WT	WT
LPV/r control	F	13	17	<400	35	2500	-	WT	WT
LPV/r control	M	9	18	<50	35	59600	-	WT	WT
LPV/r control	M	6	16	<400	31	3940	-	K103N	WT
LPV/r control	M	13	19	<50	50	2850	WT	-	-
LPV/r control	M	8	21	114	33	5260	WT	WT	M184I, A62V
LPV/r control	M	9	16	<50	28	100000	WT	WT	WT
LPV/r control	F	6	15	70	19	69800	WT	WT	WT
LPV/r control	F	8	17	152	25	35700	WT	WT	M184V
LPV/r control	F	2	16	<50	30	8160	Y181C	WT	A62V, M184V, K219R
NVP Switch	F	3	22	91	34	90200	-	K103N	M184I
NVP Switch	M	14	30	170	33	100000	-	K103N, Y181C	M184V
NVP Switch	M	10	20	<50	28	4210	-	V106M, Y181C, Y188C	K65R, M184V
NVP Switch	M	8	20	192	23	94300	-	Y181C	M184V
NVP Switch	M	4	16	<50	20	15660	-	Y181C	M184I
NVP Switch	M	10	16	134	22	1442	K103N	-	-
NVP Switch	F	14	27	<50	31	70800	WT	K101E, G190A	M184V
NVP Switch	F	9	16	<50	28	7640	WT	WT	WT
NVP Switch	M	9	16	<50	19	36800	WT	WT	WT
NVP Switch	F	17	25	252	29	6900	WT	V106A	M184V
NVP Switch	F	16	26	<50	31	2310	WT	V106A	M184V
NVP Switch	M	8	22	<50	25	1090	WT	Y181C	M184V
NVP Switch	M	11	19	218	22	4260	WT	Y181C	M184V
NVP Switch	F	3	13	<50	20	361000	Y181C	WT	WT
NVP Switch	M	10	18	132	28	4700	Y181C	V106M, Y181C	M184V
NVP Switch	F	17	30	<50	31	3000	Y181C	Y181C	T69N
NVP Switch	M	7	16	<50	25	100000	Y181C	Y181C	WT
NVP Switch	F	7	14	<50	24	1350	Y181C	Y181C	M184I
NVP Switch	M	17	31	221	32	100000	Y181C	Y181C	D67N
NVP Switch	M	10	17	<50	29	4360	Y181C	Y181C	M184I
NVP Switch	F	11	25	61	33	18880	Y181C	Y181C, K103N	L74V, M184V
NVP Switch	F	7	14	<50	17	7560	Y188C	K101E, Y181C	M184V

^*WT indicates wild type; - indicates no result